Matthew Lee

Matthew Lee is an associate in Goodwin’s Technology and Life Sciences group in London. Matthew advises clients on a broad range of corporate matters, with a focus on transactions in the life sciences, healthcare and technology sectors. He has particular experience advising on mergers and acquisitions, corporate finance and  capital markets transactions, as well as general corporate matters.

Prior to joining Goodwin, Matthew was an associate in the Corporate Finance and M&A department at Bryan Cave Leighton Paisner LLP.

Matthew’s representative experience includes:

• Acorai on its $4.5 million oversubscribed series seed financing round led by Solardis Health Ventures. Acorai is developing a non-invasive intracardiac pressure monitoring device to improve heart failure management for more than 64 million patients worldwide.
• Quanta Dialysis Technologies on multiple private funding rounds including its most recent $245 million oversubscribed Series D funding round, the largest private funding round for a dialysis device company in history.
• Achilles Therapeutics plc on its Initial Public Offering on NASDAQ with total proceeds of $175.5 million. Achilles is a biopharmaceutical company developing personalised cancer immunotherapies. 
• Achilles Therapeutics on the completion of its £52.7 million Series C. 
• COMPASS Pathways plc on its public follow-on offering on NASDAQ of American Depositary Shares for gross proceeds of approximately $144 million.
• COMPASS Pathways plc on its $146.6 million initial public offering on NASDAQ. Compass is a life sciences company dedicated to accelerating patient access to evidence based innovation in mental health.
• Rockend Limited, a company aiming to create novel cell therapeutics on its seed financing and subsequent seed extension financing.
• Wintermute Trading Limited, a leading global crypto market maker, on their $20 million Series B funding round.
• Wintermute Trading Limited on its $2.8 million Series A financing.